Based on the data presented above and the current understanding of the proposed mode of action (Figure 6), we conclude that hemopexin is a promising new candidate to treat acute vaso-occlusive crises in people living with SCD, and provides a basis for clinical development for this indication. Here, HPX is linked to Schnyder corneal dystrophy.